If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.

Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...

COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ...

The CHIKV VLP vaccine – which has the trade name Vimkunya in the EU – is also the first vaccine in the EU to protect adolescents from the age of 12 as well as adults from chikungunya ...

If granted, the marketing authorization of VIMKUNYA would be valid in all EU member states, as well as in Iceland, Liechtenstein, and Norway. Based on the positive CHMP opinion, Bavarian Nordic ...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in ...